Published in Genome Med on November 25, 2016
The ENCODE (ENCyclopedia Of DNA Elements) Project. Science (2004) 38.24
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99
International network of cancer genome projects. Nature (2010) 20.35
Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov (2008) 12.72
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science (2015) 11.89
The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet (2013) 11.29
Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature (2012) 10.39
Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science (2015) 9.92
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
Cancer drug resistance: an evolving paradigm. Nat Rev Cancer (2013) 6.77
A whole-cell computational model predicts phenotype from genotype. Cell (2012) 5.98
Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell (2012) 5.92
Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer (2006) 5.58
Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell (2015) 5.10
Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol (2006) 3.63
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res (2010) 3.54
Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol (2009) 3.49
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science (2015) 3.12
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response. Nat Med (2015) 2.95
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med (2015) 2.88
Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell (2015) 2.79
Tumor heterogeneity and personalized medicine. N Engl J Med (2012) 2.63
Addressing genetic tumor heterogeneity through computationally predictive combination therapy. Cancer Discov (2013) 2.59
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell (2015) 2.52
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer (2016) 2.19
A Landscape of Pharmacogenomic Interactions in Cancer. Cell (2016) 2.07
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis (2014) 2.07
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (2016) 1.95
Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Proc Natl Acad Sci U S A (2014) 1.89
Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57
Targeting the DNA Damage Response in Cancer. Mol Cell (2015) 1.57
Cell-to-Cell Variation in p53 Dynamics Leads to Fractional Killing. Cell (2016) 1.55
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res (2014) 1.54
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer. Cell (2015) 1.50
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture. Nat Med (2014) 1.47
Perturbation biology nominates upstream-downstream drug combinations in RAF inhibitor resistant melanoma cells. Elife (2015) 1.46
Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nat Rev Clin Oncol (2012) 1.27
A community computational challenge to predict the activity of pairs of compounds. Nat Biotechnol (2014) 1.24
Mitigating the toxic effects of anticancer immunotherapy. Nat Rev Clin Oncol (2014) 1.23
Gut microbiota, metabolites and host immunity. Nat Rev Immunol (2016) 1.22
Defining principles of combination drug mechanisms of action. Proc Natl Acad Sci U S A (2012) 1.19
Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. Cancer Res (2015) 1.15
Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal (2013) 1.07
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. Immunity (2016) 1.07
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov (2016) 1.06
Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest (2015) 1.04
Deep phenotyping: The details of disease. Nature (2015) 1.04
Universes collide: combining immunotherapy with targeted therapy for cancer. Cancer Discov (2014) 1.03
Systems pharmacology for drug discovery and development: paradigm shift or flash in the pan? Clin Pharmacol Ther (2013) 1.03
The cytotoxic T cell proteome and its shaping by the kinase mTOR. Nat Immunol (2015) 1.00
Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release (2014) 1.00
Bridging the layers: towards integration of signal transduction, regulation and metabolism into mathematical models. Mol Biosyst (2013) 0.98
Microbiome and Anticancer Immunosurveillance. Cell (2016) 0.97
Computational genomics tools for dissecting tumour-immune cell interactions. Nat Rev Genet (2016) 0.94
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer. Cancer Immunol Res (2015) 0.93
Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data. Front Oncol (2015) 0.92
Systems biology approaches for advancing the discovery of effective drug combinations. J Cheminform (2015) 0.90
Angiogenic activity of breast cancer patients' monocytes reverted by combined use of systems modeling and experimental approaches. PLoS Comput Biol (2015) 0.88
Deep learning for computational biology. Mol Syst Biol (2016) 0.88
Modelling of compound combination effects and applications to efficacy and toxicity: state-of-the-art, challenges and perspectives. Drug Discov Today (2015) 0.87
Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling. PLoS Comput Biol (2015) 0.84
Trans-Omics: How To Reconstruct Biochemical Networks Across Multiple 'Omic' Layers. Trends Biotechnol (2016) 0.84
Logical Modeling and Dynamical Analysis of Cellular Networks. Front Genet (2016) 0.84
Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov. Pac Symp Biocomput (2015) 0.84
Mathematical Modeling of Therapy-induced Cancer Drug Resistance: Connecting Cancer Mechanisms to Population Survival Rates. Sci Rep (2016) 0.83
Benefits of mTOR kinase targeting in oncology: pre-clinical evidence with AZD8055. Biochem Soc Trans (2011) 0.83
Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol (2016) 0.82
Network biology concepts in complex disease comorbidities. Nat Rev Genet (2016) 0.82
Mobile data: Made to measure. Nature (2015) 0.82
Androgen-Induced TMPRSS2 Activates Matriptase and Promotes Extracellular Matrix Degradation, Prostate Cancer Cell Invasion, Tumor Growth, and Metastasis. Cancer Res (2015) 0.81
Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Cell (2016) 0.81
Immunometabolism of regulatory T cells. Nat Immunol (2016) 0.80
Modeling Signaling Networks to Advance New Cancer Therapies. Annu Rev Biomed Eng (2015) 0.80
Harnessing the intestinal microbiome for optimal therapeutic immunomodulation. Cancer Res (2014) 0.80
IBM Watson: How Cognitive Computing Can Be Applied to Big Data Challenges in Life Sciences Research. Clin Ther (2016) 0.79
Network pharmacodynamic models for customized cancer therapy. Wiley Interdiscip Rev Syst Biol Med (2015) 0.79
Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck. Curr Treat Options Oncol (2016) 0.79
Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings. CPT Pharmacometrics Syst Pharmacol (2015) 0.78
Transcriptional Characterization of Compounds: Lessons Learned from the Public LINCS Data. Assay Drug Dev Technol (2016) 0.78
Modeling tumor response after combined administration of different immune-stimulatory agents. J Pharmacol Exp Ther (2013) 0.78
Can Targeting Stroma Pave the Way to Enhanced Antitumor Immunity and Immunotherapy of Solid Tumors? Cancer Immunol Res (2016) 0.78
Toward synthesizing executable models in biology. Front Bioeng Biotechnol (2014) 0.77
Fine-Tuning Cancer Immunotherapy: Optimizing the Gut Microbiome. Cancer Res (2016) 0.77
Big data in biomedicine. Nature (2015) 0.77
Artificial intelligence. DARPA sets out to automate research. Science (2015) 0.76
Fibroblasts, an inconspicuous but essential player in colon cancer development and progression. World J Gastroenterol (2016) 0.76
Systematic Analysis of Quantitative Logic Model Ensembles Predicts Drug Combination Effects on Cell Signaling Networks. CPT Pharmacometrics Syst Pharmacol (2016) 0.76
Two is better than one; toward a rational design of combinatorial therapy. Curr Opin Struct Biol (2016) 0.76
Shaping Tumor Microenvironment for Improving Nanoparticle Delivery. Curr Drug Metab (2016) 0.76
An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. Mol Cancer Ther (2016) 0.76
Integrating Multiscale Modeling with Drug Effects for Cancer Treatment. Cancer Inform (2016) 0.76
Cancer network activity associated with therapeutic response and synergism. Genome Med (2016) 0.76